EN DE
Watch PDS Biotechnology Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PDS Biotechnology Corporation (PDSB) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of PDS Biotechnology Corporation stock $1.39, price $1.44, upside -3.3%, quality 42 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PB PDS Biotechnology Corporation logo Thin data Oct 30, 2026

PDS Biotechnology Corporation

PDSB · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value $1.39 · Fairly valued (−3.3%)
Quality 42/100
Moderate debt
Mixed vs. peers (3/7)
Negative free cash flow
Narrow moat 30/100 · thin data
Thin data
⚠ Dilution
Watch PDS Biotechnology Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$17.08 $0.2010 Fair Value $1.39 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

60‑month range $0.2010 – $17.08 · fair‑value band $1.05 – $1.74 · the $1.44 price screens above the $1.39 fair value. As of Oct 30, 2026.

Follow PDS Biotechnology in your weekly email

Every Wednesday you see whether PDS Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.

Show moreShow less

The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.

In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.

It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Stock analysis

PDS Biotechnology Corporation (PDSB) currently trades at $1.44, while our model-based Fair Value estimate is $1.39, so the stock looks roughly fairly valued today (gap 3.4%).

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.05 (bear) to $1.74 (bull), the price of $1.44 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

PDS Biotechnology Corporation reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$34.5M in FY2025.

Key figures

Market cap $163M Micro · EPS (TTM) $−0.6500 · Return on equity −544% · Return on assets (EBIT) −68.4% · Free cash flow −$27.8B · Net cash $9.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 616% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −3%, PDSB screens richer than that median.

Fair Value models

Bear $1.05 Fair Value $1.39 Bull $1.74
Price $1.44 · Upside -3.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA $1.23 $1.64 $2.05 67
NCAV (Graham) $0.0003 $0.0006 $0.0006 55
All 2 models by family
Multiples
EV/EBITDA $1.23 $1.64 $2.05 67
Asset-Based
NCAV (Graham) $0.0003 $0.0006 $0.0006 55

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 100
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 24
How calm the share price moves, does not count
Momentum 65
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 85
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch PDSB, get fair value alerts →

Compare PDS Biotechnology Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 588 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −10.1% · Above median
Profitability
Return on assets −113.1% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 1.27× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 17.59× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)37 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $116.80 $203.62 +74% vs PDSB
Regeneron Pharmaceuticals, Inc REGN $818.77 $1,275 +56% vs PDSB
Vertex Pharmaceuticals Incorporated VRTX $540.00 $594.00 +10% vs PDSB
Samsung Biologics Co 207940 1,487,000 KRW 1,635,700 KRW +10% vs PDSB
WuXi Biologics (Cayman) Inc 2269 HK$45.06 HK$49.57 +10% vs PDSB
argenx SE ARGX $882.48 $908.40 +3% vs PDSB
CSL Limited CSL A$200.73 A$178.58 −11% vs PDSB
BeOne Medicines AG 6160 HK$217.60 HK$153.56 −29% vs PDSB
Celltrion, Inc 068270 189,300 KRW 74,945 KRW −60% vs PDSB
Royalty Pharma plc RPRX $64.76 $19.01 −71% vs PDSB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PDS Biotechnology Corporation · Fair Value
$1.39 −3%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "PDS Biotechnology Corporation Fair Value". https://www.fairvalue-calculator.com/stock/PDSB

Frequently asked questions

Is PDS Biotechnology Corporation (PDSB) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $1.39 versus a price of $1.44, about −3% upside (fairly valued).
What is the fair value of PDSB?
Our model-based fair value for PDS Biotechnology Corporation is $1.39 (as of Oct 30, 2026), built from audited fundamentals. The current price: $1.44.
What is the quality score of PDSB?
PDS Biotechnology Corporation has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PDS Biotechnology Corporation (PDSB)?
Our model-based price target is the fair value of $1.39 (as of Oct 30, 2026) from 2 valuation models. Cautious scenario $1.05, optimistic scenario $1.74. It is a calculation from audited fundamentals, not an analyst target.
What is the PDS Biotechnology Corporation stock forecast for 2026?
Our models put fair value at $1.39, about −3% upside versus a price of $1.44 (fairly valued). Cautious scenario $1.05, optimistic scenario $1.74. The calculation is refreshed regularly with new filings.
What is the intrinsic value of PDS Biotechnology Corporation (PDSB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PDS Biotechnology Corporation it is $1.39 per share (as of Oct 30, 2026), against a price of $1.44. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is PDS Biotechnology Corporation stock overvalued or undervalued in 2026?
As of Oct 30, 2026, PDSB trades above its calculated fair value: price $1.44, fair value $1.39, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PDSB?
No. The price is what the market pays today ($1.44); the fair value is what the company's own numbers justify ($1.39). For PDS Biotechnology Corporation the two are $0.0470 per share apart. That gap is exactly why we show both numbers side by side.
How much is PDS Biotechnology Corporation worth?
The market values PDS Biotechnology Corporation at about $163M (market capitalisation, as of Oct 30, 2026). Per share that is $1.44; our models calculate a fair value of $1.39 per share.
What do the bullish and bearish scenarios say about PDSB?
Our models span a range for PDS Biotechnology Corporation: cautious scenario $1.05, base $1.39, optimistic $1.74 per share (as of Oct 30, 2026, price $1.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PDS Biotechnology Corporation (PDSB)?
Balance-sheet figures for PDS Biotechnology Corporation (as of Oct 30, 2026): debt of 1.27 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is PDSB from its 52-week high?
PDS Biotechnology Corporation trades at $1.44, about 10% below its 52-week high of $1.60 and 616% above the low of $0.2010 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $1.39 is for.
Which stocks are comparable to PDS Biotechnology Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PDS Biotechnology Corporation stock attractive at the current price?
The data as of Oct 30, 2026: price $1.44, calculated fair value $1.39 (−3%), Quality Score 42/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PDSB calculated?
We run PDS Biotechnology Corporation through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.39, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. PDS Biotechnology Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PDS Biotechnology Corporation (PDSB)?
The closing price on Oct 30, 2026 was $1.44. Our model-based fair value is $1.39, about −3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PDS Biotechnology Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of PDS Biotechnology Corporation

How large is the market capitalisation of PDS Biotechnology Corporation (PDSB)?
The market capitalisation of PDS Biotechnology Corporation is $163M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of PDS Biotechnology Corporation (PDSB)?
Earnings per share at PDS Biotechnology Corporation are $−0.6500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of PDS Biotechnology Corporation (PDSB)?
The return on equity (ROE) of PDS Biotechnology Corporation is −544% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PDS Biotechnology Corporation (PDSB)?
On an EBIT basis the return on assets of PDS Biotechnology Corporation is −68.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does PDS Biotechnology Corporation (PDSB) generate?
The free cash flow of PDS Biotechnology Corporation is −$27.8B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does PDS Biotechnology Corporation (PDSB) hold?
PDS Biotechnology Corporation holds more cash than debt, $9.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch PDS Biotechnology Corporation in the live analysis

One click puts PDS Biotechnology Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.